Phaseline

Companies › Triumvira Immunologics

Triumvira Immunologics: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 1; Oncology; next expected readout Aug 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
TAC01-CLDN18.2
anti-CLDN18.2 T-cell Antigen Coupler (TAC) engineered autologous T cell therapy
–Phase 1Metastatic Solid TumorAug 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT05862324TAC01-CLDN18.2Phase 1Metastatic Solid TumorOncologyAug 2027

Targets

No annotated target.

Companies with the same targets

–

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.